Arbutus Biopharma Corp Increase (Decrease) in Contract with Customer, Asset
Arbutus Biopharma Corp (ABUS) reported Increase (Decrease) in Contract with Customer, Asset of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2020-03-05
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for the quarter ending 2019-12-31 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for the quarter ending 2019-09-30 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for the quarter ending 2019-06-30 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for the quarter ending 2019-03-31 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for fiscal 2019 was $0.00.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for fiscal 2018 was -$128.00K.
- Arbutus Biopharma Corp increase (decrease) in contract with customer, asset for fiscal 2017 was $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | $0.00 10-K · filed 2020-03-05 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | $0.00 derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | $0.00 derived: sum of 4 quarters · filed 2020-03-05 |
| 2019-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | $0.00 derived: sum of 3 quarters · filed 2020-03-05 | -$128.00K derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $0.00 derived: sum of 2 quarters · filed 2020-03-05 | -$128.00K derived: sum of 3 quarters · filed 2020-03-05 | -$128.00K 10-K · filed 2020-03-05 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-06 | -$128.00K derived: sum of 2 quarters · filed 2019-11-06 | -$128.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$128.00K 10-Q · filed 2019-08-05 | -$128.00K 10-Q · filed 2019-08-05 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 10-K · filed 2019-03-07 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |